Follow
'Many startups initially faced an uphill battle persuading investors of the clinical opportunities in the dark genome. “They’re tainted with the assumption of non-functionality and non-importance,” says Joseph Dukes, CSO at Oxford, UK-based Enara Bio, a company engaged in scanning the dark genome for antigens that may offer fruitful targets for cancer #immunotherapy'
#Immunology
